Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 13/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 2/20 | 0.38 |
| ▸ | CFTR | P13569 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3414341 | 1.00 | CNR2 (0.42) | CNR2CNR1HPGDSCFTR | |
| SCHEMBL3407617 | 1.00 | CNR2 (0.42) | CNR2CNR1HPGDSCFTR | |
| SCHEMBL528718 | 0.83 | CNR1 (0.56) | CNR2CNR1HPGDS | |
| SCHEMBL528709 | 0.82 | CNR1 (0.46) | CNR2CNR1HPGDS | |
| SCHEMBL529274 | 0.82 | CNR1 (0.46) | CNR2CNR1HPGDS | |
| SCHEMBL528708 | 0.82 | CNR1 (0.46) | CNR2CNR1HPGDS | |
| SCHEMBL528736 | 0.81 | CNR1 (0.46) | CNR2CNR1 | |
| SCHEMBL4237845 | 0.75 | CNR1 (0.52) | CNR2CNR1 | |
| SCHEMBL4243134 | 0.75 | CNR1 (0.52) | CNR2CNR1 | |
| SCHEMBL4242251 | 0.75 | CNR1 (0.52) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2262770-B1 | 2-TRIFLUOROMETHYLNICOTINAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | HOFFMANN LA ROCHE (CH) | 2012-08-01 | — | — | EP | disclosed |
| US-7897621-B2 | 2-trifluoromethylnicotinamide derivatives as HDL-cholesterol raising agents | HOFFMANN-LA ROCHE INC. (US) | 2011-03-01 | — | — | US | disclosed |
| EP-2262770-A1 | 2-TRIFLUOROMETHYLNICOTINAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | F. Hoffmann-La Roche AG (CH) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009121740-A1 | 2-TRIFLUOROMETHYLNICOTINAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-08 | — | — | WO | disclosed |
| US-20090247588-A1 | 2-TRIFLUOROMETHYLNICOTINAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | HOFFMANN-LA ROCHE, INC. | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247588-A1 | 2-TRIFLUOROMETHYLNICOTINAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | CETP, APOB, NPC1 | CNR2 1312/4885CNR1 910/4885HPGDS 4382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.